Edgen
免费试用 Ed
Ryan Patel - Healthcare & Life Sciences Analyst at Edgen

Ryan Patel

Healthcare & Life Sciences Analyst

Drug pipelines, FDA catalysts, and biotech valuation. Came from equity research at Jefferies covering mid-cap pharma. His analysis tends to be contrarian — he'll downgrade a consensus favorite if the Phase 3 data doesn't hold up to scrutiny.
Latest
AbbVie评级买入，目标价$250。FY2025营收$61.16B（+10.6%），Skyrizi+Rinvoq年化收入接近$27B，自由现金流$17.8B，股息贵族。完整分析请访问Edgen。

AbbVie 股票分析：Skyrizi 和 Rinvoq 重新定义制药投资逻辑 | Edgen

The global pharmaceutical industry in 2026 is navigating a structural transformation driven by three converging forces: the largest patent cliff cycle in the sector's history, the implementation of the Inflation Reduction Act's drug price negotiation provisions, and a widening bifurcation between companies with genuine innovation engines and those reliant on mature, commoditizing portfolios. Between 2023 and 2030, branded drugs representing over $250 billion in peak annual revenue will lose patent protection, exposing companies to biosimilar and generic competition that typically erodes 60-80% of branded revenue within three to five years of exclusivity loss. AbbVie's Humira, which peaked at $21.2 billion in annual sales in 2022 as the world's best-selling drug, was the poster child for this risk. The drug's U.S. biosimilar entry in January 2023 triggered an immediate and sustained revenue decline — Humira revenue fell to approximately $14.4 billion in FY2023, then approximately $10.2
Ryan Patel
·
Apr 20 2026

投资这事，终于不用一个人了

免费试用 Ed。不用信用卡，不绑约
免费试用 Ed